Leukemia

MBG453 combined with decitabine or azacitidine was safe and well-tolerated by patients with myelodysplastic syndrome or acute myeloid leukemia. Both combinations showed encouraging antileukemic activity and response rates. Read More ›

Among patients with relapsed/refractory acute myeloid leukemia, CPX-351 plus 7 days of venetoclax was tolerable and demonstrated encouraging activity. Read More ›

Superior outcomes were observed for older patients with AML receiving decitabine + venetoclax for 10 days versus intensive chemotherapy in a propensity score–matched analysis, particularly for those at high risk for treatment-related mortality. Read More ›

The addition of venetoclax to azacitidine in treatment-naïve patients with AML ineligible for intensive therapy because of medical comorbidities and/or advanced age (≥75 years) produced significantly greater response rates and overall survival versus azacitidine alone. Read More ›

Ivosidenib monotherapy demonstrated prolonged overall survival and the potential to increase complete response rates in relapsed or refractory IDH1-mutated acute myeloid leukemia (AML) compared with standard-of-care therapies in a historical control population. Read More ›

The QUAZAR study evaluating CC-486 (oral azacitidine) illustrated that CC-486 does not negatively impact health-related quality of life compared with placebo. Read More ›

This study in younger and older patients with newly diagnosed, FLT3-mutated acute myeloid leukemia (AML) showed that midostaurin + chemotherapy resulted in high response rates, regardless of patient age. Read More ›

The combination of enasidenib and azacitidine resulted in a significant increase in response rate when compared with azacitidine alone in patients with mutant IDH2 newly diagnosed AML. This combination therapy was well-tolerated. Read More ›

Patient-specific doses of iodine-131-apamistamab resulted in consistent engraftment following allogeneic hematopoietic stem-cell transplantation among patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Read More ›

Patients with FLT3 mutation–positive R/R AML who relapsed on gilteritinib therapy were found to have acquired new mutations that were not present at baseline. The most common mutations occurred in RAS/MAPK pathway genes and FLT3.Patients with mutations in RAS/MAPK pathway genes at baseline still benefited from gilteritinib therapy. Read More ›